VIAL
Home/Compounds/IGF-1
PeptideGrey AreaClinical Trials

IGF-1

About

About IGF-1

Insulin-like growth factor 1 (IGF-1) is the primary mediator of GH anabolic effects and is produced mainly in the liver. Recombinant IGF-1 (mecasermin) is FDA-approved for severe primary IGF-1 deficiency. In optimization medicine, lr3-IGF-1 (a longer-acting analog) is used off-label for muscle growth, recovery, and neuroprotection. It is a potent anabolic compound requiring careful titration.

Science

Mechanism of Action

Binds IGF-1 receptors on muscle, bone, and neural tissue, activating PI3K/Akt/mTOR signaling pathways to promote protein synthesis, cell survival, glucose uptake, and neural plasticity.

Dosing

Typical Protocol

20–80 mcg subcutaneous injection once daily post-workout; lr3-IGF-1 used at 20–100 mcg with longer activity window.

⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.

Regulatory

Legal Status in 2026

Grey Area

This compound occupies a regulatory grey area in 2026. It is neither explicitly FDA-approved nor clearly illegal for personal use, but it lacks formal clinical approval and may not be legally sold for human use in all contexts. Proceed with caution: source quality is variable, and regulatory status can change. Always consult a physician.

Evidence

Evidence Tier

Clinical Trials

Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.

Find a Verified Provider

See which Vial-verified providers offer IGF-1 — with trust scores, legal credentials, and pricing transparency.

Browse all verified providers →